Research programme: chitosan-encapsulated inflammatory bowel disease therapeutics - AdvancellAlternative Names: ANs42
Latest Information Update: 16 Jul 2016
At a glance
- Originator Advancell
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Crohn's disease; Ulcerative colitis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Ulcerative-colitis in Spain
- 16 Jul 2016 No recent reports of development identified for preclinical development in Crohn's-disease in Spain
- 20 Apr 2012 Preclinical trials in Ulcerative colitis in Spain (unspecified route)